VEGFA and neutropenia: As for most common AEs, anti-VEGF addition did affect diarrhea, vomiting, asthenia and neutropenia risk (RR 1.43, 95% CI 1.31–1.56; p < 0.00001, Supplementary Materials Figure S5).